

Special Issue

Multimodal Treatment for Pancreatic Cancer

Message from the Guest Editor

Pancreatic cancer is the fourth leading cause of cancer-related deaths in western countries, and it will become the second leading cause of gastrointestinal cancer deaths in the coming years. Surgery and adjuvant therapy remain the standard treatment, but the recurrence rate is still high. As novel therapies are regularly introduced, the optimal treatment approaches for this aggressive cancer are becoming more complex. So, multimodality treatment, i.e., neoadjuvant therapy and combination of chemotherapy, radiotherapy, immunotherapy, loco-regional therapy and surgery, is now increasingly being applied and appears essential in obtaining better results.

The aim of this Special Issue is to focus on the results and problems of multimodality therapy for resectable, locally advanced, or metastatic pancreatic cancer, the search for prognostic factors for early and late outcomes after therapy, and the evaluation of novel strategies for individualized treatment. Up-to-date original research, short communications, and comprehensive review articles on all modalities playing a role in the treatment of pancreatic cancer will be welcomed

Guest Editor

Dr. Cosimo Sperti

Department of Surgery, Oncology and Gastroenterology, Hepatobiliary and Pancreatic Surgery Unit, University of Padua, Padua, Italy

Deadline for manuscript submissions

closed (31 July 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/205140

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)